BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12800797)

  • 1. First clinically useful marker for lung cancer identified.
    Oncology (Williston Park); 2003 May; 17(5):737-8. PubMed ID: 12800797
    [No Abstract]   [Full Text] [Related]  

  • 2. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study.
    Suzuki S; Dobashi Y; Sakurai H; Nishikawa K; Hanawa M; Ooi A
    Cancer; 2005 Mar; 103(6):1265-73. PubMed ID: 15712203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
    Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular biologic staging of lung cancer.
    D'Amico TA
    Ann Thorac Surg; 2008 Feb; 85(2):S737-42. PubMed ID: 18222207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.
    Singhal S; Vachani A; Antin-Ozerkis D; Kaiser LR; Albelda SM
    Clin Cancer Res; 2005 Jun; 11(11):3974-86. PubMed ID: 15930332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor-associated prognostic parameters in non-small-cell bronchial carcinoma].
    Thomas M
    Pneumologie; 1997 Jul; 51(7):669-77. PubMed ID: 9333800
    [No Abstract]   [Full Text] [Related]  

  • 8. Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer.
    Lin X; Gu J; Lu C; Spitz MR; Wu X
    Clin Cancer Res; 2006 Oct; 12(19):5720-5. PubMed ID: 17020976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of cytokeratin 19 mRNA expression in peripheral leucocytes in patients with non-small cell lung cancer].
    Wang ZH; Kong L; Liu J
    Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):53. PubMed ID: 17575695
    [No Abstract]   [Full Text] [Related]  

  • 11. Absence of prognostic significance of p21(WAF1/CIP1) protein expression in non-small cell lung cancer.
    Dworakowska D; Jassem E; Jassem J; Boltze C; Wiedorn KH; Dworakowski R; Skokowski J; Jaśkiewicz K; Czestochowska E
    Acta Oncol; 2005; 44(1):75-9. PubMed ID: 15848909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
    Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
    Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
    Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
    Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
    Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
    Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
    Hsu CP; Shen GH; Ko JL
    Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical significance of cyclin Dl expression in non-small cell lung cancer].
    Dworakowska D
    Pneumonol Alergol Pol; 2005; 73(3):297-300. PubMed ID: 16989170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new tumor suppressor gene: invasion, metastasis, and angiogenesis as potential key targets.
    Albini A; Pfeffer U
    J Natl Cancer Inst; 2006 Jun; 98(12):800-1. PubMed ID: 16788148
    [No Abstract]   [Full Text] [Related]  

  • 19. Distribution of Bcl-2 gene expression and its prognostic value in non-small cell lung cancer.
    Yilmaz A; Savaş I; Dizbay Sak S; Güngör A; Kaya A; Serinsöz E; Savaş B
    Tuberk Toraks; 2005; 53(4):323-9. PubMed ID: 16456730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of mutational changes in involved N1 lymph nodes with those in primary tumors in stage II non-small cell lung cancer: a pilot study.
    Fernando HC; Sasatomi E; Christie NA; Buenaventura PO; Finkelstein SD; Yousem SA; Soose R; Close JM; Luketich JD
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):87-91. PubMed ID: 14752417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.